The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 12, 2022

Filed:

Jun. 09, 2020
Applicant:

George Mason University, Fairfax, VA (US);

Inventors:

Yuntao Wu, Fairfax, VA (US);

Yajing Fu, Fairfax, VA (US);

Deemah Dabbagh, Fairfax, VA (US);

Zheng Zhou, Fairfax, VA (US);

Assignee:

George Mason University, Fairfax, VA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/12 (2006.01); A61P 31/18 (2006.01); C12N 7/00 (2006.01); A61K 39/21 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/21 (2013.01); A61K 39/12 (2013.01); A61P 31/18 (2018.01); C12N 7/00 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/5256 (2013.01); C12N 2740/16042 (2013.01);
Abstract

Embodiments relate to methods comprising expressing or overexpressing P-selectin glycoprotein ligand-1 (PSGL-1) in human immunodeficiency virus (HIV) producing cells; isolating HIV particles from the HIV producing cells; and preparing the isolated HIV particles as a HIV vaccine. Embodiments relate to systems comprising a HIV vaccine comprising live attenuated, inactivated, or non-infectious HIV particles. Embodiments relate to systems capable of performing a method comprising administering a vaccine comprising live attenuated, inactivated, or non-infectious HIV particles to a subject in need of the vaccine; and treating or preventing one or more disease states in the subject resulting from HIV infection. Embodiments relate to methods comprising expressing or overexpressing PSGL-1 in virus producing cells; and inhibiting viral infection; or inhibiting viral spreading; or inactivating viruses and virus producing cells; or producing non-infectious virion particles; or allowing the virus producing cells to produce non-infectious virions, isolating the virions, and preparing non-infectious virions, the virions being HIV particles.


Find Patent Forward Citations

Loading…